Lyra Therapeutics (NASDAQ:LYRA) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.23) by 21.74 percent. The company reported quarterly sales of $195.000 thousand which missed the analyst consensus estimate of $320.000 thousand by 39.06 percent. This is a 64.15 percent decrease over sales of $544.000 thousand the same period last year.